Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Kite and Arcellx will jointly advance and commercialize the CART-ddBCMA asset in the U.S., and Kite will commercialize the product outside the U.S.Īrcellx, Inc. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.Ĭurrently being investigated in a Phase 2 pivotal trial, CART-ddBCMA is Arcellx’s T-cell therapy utilizing the company’s novel synthetic binder, the D-Domain. ![]() (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. Gilead expects the deal to close in the fourth quarter of this year.SANTA MONICA, Calif. "Now is the right time to get involved in this kind of therapy."Ĥ. "It really became clear that was going to work, and it was going to work in more than one kind of tumor … And then, importantly, that the manufacturing on an industrial scale could work," Gilead CEO John Milligan said during an investor's call, according to Reuters. Gilead hopes to break into the CAR-T cancer drug market to make up for waning sales of its hepatitis C drugs. Kite Pharma is developing a chimeric antigen receptor T-cell therapy, which spurs a patient's immune cells to identify and attack cancer cells.ģ. Gilead will pay $180 per share for Kite Pharma in an all-cash deal.Ģ. Here are four things to know about the deal.ġ. Gilead Sciences on Monday agreed to purchase Kite Pharma for $11.9 million, reports Reuters.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |